How much is Ikena Oncology worth in 2026?

Ikena Oncology has a current valuation of N/A based on their Later Stage VC (Series B) round and secondary market data.

How much funding has Ikena Oncology raised?

Ikena Oncology has raised N/A in total funding across 1 funding rounds.

Ikena Oncology

Drug Discovery

Ikena Oncology valuation and funding history | Last updated: January 5, 2021 | 1 funding rounds

Current Valuation

N/A

As of January 5, 2021

Total Funding Raised

N/A

Across 1 round

Last Round

Later Stage VC (Series B)

$120.0M

Last Funding

Jan 2021

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
January 5, 2021	Later Stage VC (Series B)	$120.0M	N/A	-

Valuation Analysis

Current Valuation Metrics

Ikena Oncology is currently valued at N/A as of January 5, 2021.

Track Ikena Oncology Valuation Updates

Get notified when Ikena Oncology raises new funding or valuation changes

Explore More Data

Detailed analysis for Ikena Oncology

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock Ikena Oncology's valuation history, funding rounds, and growth metrics.

No credit card required

What is Ikena Oncology Worth in 2026?

Ikena Oncology is a leading private company in the Drug Discovery sector. Track Ikena Oncology's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How Ikena Oncology Valuation is Determined

Private company valuations like Ikena Oncology's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.